Pulmonary hypertension (PH) is a rare and fatal disease characterized by elevation of the mean pulmonary artery pressure 25 mm Hg at rest or 30 mm Hg with exercise and is due to remodeling of the vasculature of the pulmonary artery and increased vasoconstriction. This disease is characterized by dyspnea initially while exercising, fatigue, dizziness or fainting, chest pressure or pain, edema of ankles, legs, ascites, cyanosis, and increased heart rate. If left untreated, it results in right ventricular failure and ultimately death.
60% in patients with left ventricular systolic dysfunction, and up to 70% in patients with isolated left ventricular diastolic dysfunction. 11 The incidence of PH is 20% in chronic obstructive pulmonary disease (COPD) patients with respiratory failure, 12 but in advanced COPD the incidence is greater than 50%. 13 The incidence of PH is 39% in patients with interstitial lung disease. 14 The incidence and prevalence of PH in chronic pulmonary thromboembolism in the Spanish population is 0.9 case/1 million/year, and 3.2 cases/1 million, respectively. 15 The incidence of PH after acute pulmonary embolism is 1.0 to 3.8%. 16 The prevalence of PH in sarcoidosis is 1 to 28%.
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Classification of PH
The clinical classification of PH has been updated. 1 PH has been classified into five groups:
1. PAH that covers idiopathic, heritable, drug-and toxininduced, associated with connective tissue diseases, HIV (human immunodeficiency virus) infection, portal hypertension, congenital systemic to pulmonary shunts, schistosomiasis, PAH responders to calcium channel blockers, persistent pulmonary hypertension of newborn syndrome, and associated with venous/capillaries (pulmonary venoocclusive disease, pulmonary capillary hemangiomatosis). 2. PH due to left heart diseases, such as heart failure, valvular heart diseases, and congenital/acquired cardiovascular conditions, leading to post capillary PH. 3. PH associated with lung diseases and/or hypoxia that include COPD, interstitial lung diseases, and hypoxia without lung diseases. 4 . PH related to chronic obstruction of pulmonary artery, such as chronic thromboembolism and other pulmonary artery obstruction. 5. PH due to unclear and/or multifactorial mechanisms that covers hematological disorders.
Hemodynamics of PH
Pulmonary hypertension is defined as mean pulmonary arterial pressure (mPAP) 25 mm Hg measured by right heart catheterization, pulmonary capillary wedge pressure (PCWP) 
Pathology of PH
Pulmonary hypertension is characterized by smooth muscle cells proliferation, muscularization of peripheral pulmonary arteries, and medial thickening of larger pulmonary arteries. Muscularization is associated with fibroblastosis, reduced responses to vasodilators, and formation of obliterative plexiform lesions. The pathophysiologic mechanisms of group 1 (PAH) have been studied in detail. However, the pathophysiologic mechanisms of groups 2 to 5 PH are not that well known. The histopathological studies, such as vasculopathy, hypertrophy of media, intimal hyperplasia and fibrosis, plexiform lesions, recanalization of thrombi, and thromboembolism, are similar in all the five groups irrespective of the differences in etiology. Increased vascular resistance in PAH is due to vasoconstriction, vascular remodeling, and thrombosis.
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Since the etiologies are different for each group, the author would like to describe the pathophysiology of each group in short. Group 1 (PAH): in this group, distal pulmonary artery is affected. The medial hypertrophy, intimal proliferation and fibrosis, adventitial thickening, inflammatory infiltration, and plexiform and thrombotic lesions characterize lesion. The mechanisms of these pathological changes are multifactorial. Hypoxia-induced pulmonary vasoconstriction leads to luminal narrowing. Hypoxia also inhibits voltage-gated potassium channel in the smooth muscle cells of pulmonary artery leading to the opening of the voltage-gated calcium channel.
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This would constrict the pulmonary artery causing dysfunction of pulmonary arterial endothelial cells resulting in decreased production of vasodilators (prostacyclin, nitric oxide [NO]), and increased production of vasoconstrictors (endothelin-1, thromboxane A 2 ). 22 Pulmonary vascular remodeling is comprised of medial hypertrophy due to proliferation of smooth muscle cells of the pulmonary artery and neointimal formation due to dysfunction and proliferation of endothelial cells. 23 Elevated production of the adventitial matrix and reduction in proteolysis of the extracellular matrix (ECM) would also contribute in remodeling of the pulmonary artery. 22 Platelets are also involved in the pathogenesis of PAH because they occlude the vessels through thrombosis and generation of NO, a vasoconstrictor. 
AGE-RAGE Stress
In the AGE-RAGE axis which is comprised of AGE, RAGE, and sRAGE, AGE and RAGE are coined as stressors, while sRAGE, enzymatic degraders of AGE (glyoxalase-1, glyoxalase-2), receptor-mediated degraders of AGE (AGER-1, AGER-2), and factors that lower the blood levels of AGE have been coined as antistressors. 35 The ratio of stressors/antistressors has been termed as AGE-RAGE stress. 35 The ratio of AGE/ sRAGE has been proposed as a simple and feasible measure of AGE-RAGE stress. 35 A high index of AGE/sRAGE would result in tissue damage and the development of diseases.
Serum Levels of AGE in PH
Serum/plasma levels of AGE in patients with PH are not available in literature. However, serum/plasma levels of AGE in diseases associated with PH are known. Plasma levels of AGE (carboxymethyl lysine [CML]) are elevated in COPD patients compared with non-COPD patients. 36 AGE levels are elevated in the lungs of patients with COPD. 37 The AGE levels are elevated in the skin of COPD patients. 38 Serum levels of AGE are significantly increased in patients with left ventricular diastolic dysfunction in type 1 diabetes 39,40 and heart failure.
41,42
Levels of RAGE in PH
The RAGE in endothelial cells of large and small pulmonary arteries, neointimal proximal remodeled pulmonary arteries, recanalized vessel-like structure of distal endarterectomized chronic thromboembolism PH (CTEPH) and idiopathic PAH (iPAH) were differently expressed.
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There is an increased expression of RAGE in smooth muscle cells of the pulmonary artery under hypoxic conditions in both humans and mice. 44 These authors also showed that the expression of RAGE was upregulated in pulmonary artery in hypoxia plus Sugen5416 (SU5416)-induced PAH mice. They also demonstrated that RAGE deletion reduced the PA pressure and restrained ECM accumulation in PA of the mouse model. Blocking RAGE activity with neutralizing antibody or genetic deletion of RAGE reduced ECM protein accumulation. 44 RAGE is one of the most upregulated proteins in PAH lung tissue of PAH patients. 45 There is an increase in the RAGE mRNA levels in human pulmonary hypertensive lung tissue compared with normotensive lung tissue, and an increase in RAGE protein levels in pulmonary artery in human pulmonary hypertensive patients compared with normotensive pulmonary artery (five-fold increase).
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They also showed that that there was no upregulation of RAGE in other tissue (brain, kidney, and peripheral muscle). Increased RAGE activation by its ligands including AGE increases RAGE expression. 28 It is possible that the increases in AGE in PH could increase the expression of RAGE. The data suggest that RAGE levels are elevated in patients with PH.
Serum/Plasma Levels of sRAGE in PH
Serum levels of sRAGE are variable in PH. Plasma levels of sRAGE were significantly lower in patients with idiopathic pulmonary fibrosis and interstitial lung disease. 47 Serum sRAGE levels are reduced in patients with emphysema.
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Serum levels of sRAGE were lower in patients with COPD than the levels in control. 38 However, there are reports where sRAGE levels have been higher in PH patients compared with controls. Plasma levels of sRAGE have been reported to be higher in patients with PH and CTEPH than those in controls.
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Serum levels of sRAGE and esRAGE were higher in patients with iPAH and CTEPH compared with control subjects. 43 The discrepancy in the serum levels of sRAGE might be due to the type of patients. High levels of sRAGE were in patients with pulmonary hypertension, while the low levels of sRAGE were in patients with lung diseases without hypertension.
Mechanism of AGE-RAGE-Induced Pulmonary Hypertension
Remodeling of pulmonary artery in PAH is due to enhanced proliferation and resistance to apoptosis of pulmonary artery smooth muscle cells. Since the histopathology of PH includes intimal hyperplasia due to an increase in the proliferation of smooth muscles and fibrosis, the focus will be on the role of AGE, RAGE, and sRAGE on smooth muscle proliferation and fibrosis. Attention will also be given to the vasoconstrictor effect of the AGE-RAGE axis. Stiffness of the pulmonary artery is due to the increased amounts of collagen, glycation of collagen, and cross-linking of collagen with AGEs. 60 The above data suggest that AGE can increase thickness and resistance of the pulmonary artery through increasing the matrix of blood vessels. As described earlier, RAGE is a multiligand receptor and combines with ligands, such as AGE, high mobility group box-1 (HMGB-1), and calcium binding calgranulin-like protein S100A4 (S100). S100 protein family consists of 24 members. Extracellular S100A4 is one of the 24 members of S100. RAGE has been implicated to play a role in many signaling pathways, such as inflammation, proliferation, and migration, all of which are associated with pathology of PH. 46 The AGE-RAGE interaction leads to the generation of ROS, and the proliferation and autophagy in vascular smooth muscle cells. 61 In vitro, S100A4 produces proliferation of human pulmonary arterial smooth muscle cells via an action non-RAGE. 62 RAGE mediates deposition of ECM fibronectin and collagen through activation of transforming growth factor-β1. 44 Vascular remodeling of the PA in PAH is characterized by deposition of ECM. 63 Binding of RAGE with HMGB-1 induces proliferation and migration of fibroblasts which are prevented by RAGE antibody. 64 
RAGE
regulates the metabolic reprogramming-induced over-proliferation in pulmonary hypertension. 65 Recently, it has been
shown that RAGE plays a crucial role in inappropriate increase in pulmonary arterial smooth muscle cells in PAH. 66 These above data suggest that AGE and its interaction with RAGE would muscularize the pulmonary artery, induce medial thickness and fibrosis, and increase stiffness in the pulmonary artery. AGE-RAGE interaction increases the generation of reactive oxygen species including Superoxide anion, hydrogen peroxide, and hydroxyl radicals. Superoxide anion produces contraction of isolated rabbit aorta which is endotheliumdependent and is partially mediated by arachidonic acid metabolism.
67 H 2 O 2 in lower concentration produces contraction, while in higher concentration, it produces transient relaxation followed by contraction of isolated rabbit aorta.
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In vivo, ROS generated by polymorphonuclear leucocytes and administration of oxygen radicals increase total peripheral vascular resistance. 
Therapeutic Approaches Targeting AGE-RAGE Axis for Pulmonary Hypertension
Current treatment of pulmonary hypertension has progressed due to pulmonary hypertension-targeted drugs. However, long-term survival of patients with PAH is still suboptimal. A search for new treatment modalities that can reverse pulmonary artery remodeling is on. Lately, attention has been focused on the AGE-RAGE axis because it is involved the pathogenesis of PH. AGE-RAGE axis (AGE, RAGE, and sRAGE) is an important therapeutic target. Reduction in AGE and RAGE levels, elevation of sRAGE levels and antioxidant are promising new therapeutic strategies in PH.
Reduction in the AGE levels
AGE levels in the body can be lowered by reducing dietary consumption of AGE, preventing AGE formation and increasing AGE degradation.
Reduction in Dietary Consumption of AGE
Glucose consumption should be reduced because glucose is involved in the synthesis of AGE. 
Antagonist of RAGE
RAGE is antagonized by the suppression of its expression, blockage of ligand binding, and inhibition of RAGE signal transduction to antagonize RAGE receptor. 46 has reported that RAGE inhibition by RAGE siRNA selectively delivered to the lungs of monocrotaline and Sugen-hypoxia-induced pulmonary hypertension in rats reversed the pulmonary hypertension. This shows that suppression of RAGE expression can indeed reverse the pulmonary hypertension.
Downregulation of RAGE expression
Blockers of RAGE Ligand Binding
Recently new drugs have been developed to block RAGE ligand binding for the treatment of Alzheimer's disease. The drugs TTP488 or PF-04494700, also known as Azeliragon, and TTP4000 prevent RAGE ligand from interacting with RAGE.
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These new drugs has been shown to be of benefit in patients with Alzheimer's disease. These drugs have not been tried in patients with PH. Inhibitors of RAGE have been discussed in detail by Bongarzone et al. 99 sRAGE RAGE activation may be prevented by sRAGE which competes with RAGE for the same ligands and therefore fewer amounts of ligands are spared to interact with RAGE to activate intracellular signaling and produce harmful effects. sRAGE can prevent RAGE signal transduction directly by preventing the homodimerization of RAGE on cell surface binding with ligands and does not activate intracellular signaling.
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Raising the Levels of sRAGE From the available data, it appears that AGE-RAGE stress is involved in the pathogenesis of PH. To date, the studies that have been performed are mostly related to RAGE in the pathogenesis of PH. The serum levels of AGE and sRAGE should be measured in the same patient so that AGE-stress can be assessed. Measurement of AGE or sRAGE individually does not provide a complete picture in the pathogenesis of PH. Plasma levels of AGE and sRAGE, and tissue levels of RAGE should be measured in animal models of PH to provide a role of AGE-RAGE stress in the pathogenesis of PH. A robust clinical trial is needed for identifying the role of AGE-RAGE stress in the pathogenesis of PH.
Considering the involvement of the AGE-RAGE axis in the development of PH, the treatment should include reduction in AGE and RAGE levels and elevation of sRAGE levels in PH patients which have been discussed earlier in detail by the author in this manuscript. Reduction of AGE levels should be an adjunct therapy along with any other treatments for PH. Consumption of acidic food, vitamins B1, B6, C, D, and E should be encouraged because these agents attenuate the synthesis of AGE. New drugs should be developed to block RAGE ligand binding. Human recombinant sRAGE should be developed for human use. Use of antioxidant vitamins, especially vitamins C and E should not be ignored. Combined use of drugs that reduce AGE levels and expression of RAGE, blocker of RAGE ligand binding, and elevation of sRAGE levels would block all pathways of the AGE-RAGE axis and hence, would be more effective than a single pathway blocker. While remembering that AGE-RAGE stress may not be the only risk factor for PH, one should not expect that.
Conclusions
The data, to date, suggest that AGE-RAGE stress may be involved in the pathogenesis of PH. AGE and its interaction with RAGE induce pulmonary vascular hypertrophy through proliferation of smooth muscle cells, accumulation of ECM and suppression of autophagy. AGE-RAGE-induced increase in ROS modulates cellular proliferation, attenuates apoptosis, and constricts the blood vessels. Increased stiffness of the artery due to vascular hypertrophy and vasoconstriction results in pulmonary hypertension. The data also suggest that the reduction in consumption and formation of AGE, suppression of RAGE expression, blockage of RAGE ligand binding, elevation of sRAGE, and antioxidant may be a novel therapeutic target for prevention, regression, and slowing of progression of PH.
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